ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013
New cancer therapies are being developed through targeted approaches that can accelerate development of more efficacious, personalized treatments. Data from such novel targets or technologies (BTK/ PI3K/ PD-1/ next-generation mAbs or ENHANZE tech/ SMDCs / Oncolytic virus / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead’s Idelalisib (PhIII); Regeneron’s REGN910 (SAR307746, PhI), REGN421 (SAR153192, PhI); Endocyte’s Vintafolide (SMDCs, PhII); Halozyme’s PEGPH20 (PhI); Infinity pharma’s IPI-145 (PhI/II); Pharmacyclics’ Ibrutinib (PhIII). This report summarizes application, competitive landscape, commercial potential of novel targets and technologies. For more detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013”.
More Publications
Dolutegravir - SAILING Data Confirms Best in Class Integrase Inhibitor - More Threat to Elvitegravir than Raltegravir
US$ 90.00
March 2013
3 pages
SymBio pharma - TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!
US$ 140.00
September 2013
3 pages
AMGN - Old is Gold = Value Buy!
US$ 140.00
November 2011
4 pages
BIOGEN IDEC - Investing for Long-Term
US$ 140.00
February 2012
9 pages
AMGEN - Dynamic Strategies in Place for Global Expansion of Innovative Drugs and Biosimilars = Growth Drivers
US$ 140.00
February 2013
6 pages
